|
|
|
|
Successful microbial manufacturing depends on optimizing strain expression and product purity, maximizing fermentation scale-up and controlling process impurities, and achieving consistently high, predictable midstream yields.
|
|
|
|
|
High refolding yields aren’t enough. Learn how analytical characterization, structural equivalence testing, and optimized fermentation reduce scale-up risk and improve quality.
|
|
|
|
|
Integrating quality early in biopharma development reduces risk, speeds commercialization, and ensures compliance through inspection readiness and ongoing analytical oversight.
|
|
|
|
|
|
|
Gain insight into how UPD ensures scalable and compliant processes, facilitates the efficient development of innovative therapeutics, and contributes to molecule development and production.
|
|
|
|
|
Mario Kraft, Director of Process Development at AGC Biologics' Heidelberg facility, explains how platform processes optimize microbial, plasmid DNA, and mRNA production.
|
|
|
|
|
|
|
With robust GMP-compliant quality systems and a broad range of regulatory qualifications, we are equipped to meet manufacturing demands at any development phase. Our microbial production platforms include both stainless steel and single-use bioreactors, offering flexible batch sizes with capacities up to 3,000 liters.
|
|
|
|
|
Transparent, collaborative outsourcing reduces supply chain risk and protects IP. Open communication and proactive problem-solving keep development on track and speed commercialization.
|
|
|
